FDA approval for ALZM means possible 3,000 pct. run on shares

ALZM Boosting Their $21 Billion Market To $60 Billion
Practically Overnight, Means
A Very Real Chance For Us To Pocket 3,000% Gains!

Their startling new technology will
expand the organ transplant market from

The dramatic expansion of this “life or death”
market makes a bidding war for ALZM almost certain!

Fellow Wealth Seeker: Allezoe Medical Holdings is poised to solve one of the biggest medical problems in the world – the 65% wastage of all organs donated for transplant! By dramatically improving the health, quality, and number of organs for transplant, Allezoe Medical (ALZM on the OTCBB exchange) will expand the current $3 billion “organ procurement market” to $6 billion, and then totally dominate it! But of even more importance to investors... because Allezoe’s revolutionary technology will stop the terrible waste of donor organs and vastly increase the number of successful transplants... The TOTAL organ transplant market will jump from $21 billion to $60 billion. Allezoe Medical expands the total market by $40 billion! And that’s what makes ALZM my #1 BUYOUT TARGET of at least a dozen medical giants, who will see the Allezoe acquisition as essential to their growth! The only possible result I can see from this “transformational event” is that ALZM shares will jump 10, 20, even 30 times higher. And here are the facts to back me up... Few people know the real reason for the extremely low organ-transplant success rate (a huge problem ALZM solves) This blockbuster investment opportunity starts with this little- known fact. Tragically, the rest die waiting or get too old or sick to stay on the waitlist. And yet, this 35% overall success rate is heartbreakingly deceiving because... If all the people who truly need an organ could “get on the waitlist,” the list would be 3 times larger. Meaning the real success rate is only 12%. For humane reasons the waitlist is severely restricted to just the top candidates, because giving false hope to 88% of all patients is deemed morally unacceptable. But now the Allezoe technology will eventually make it possible to put everybody in need on the waitlist, and thenprovide up to 80% fulfillment! Excited? I sure am! ALZM is a fortune-making opportunity for early shareholders. Just think... We’re talking about expanding a $21 billion market to $60 billion, and just one little company has the “proven technology” to make the whole thing happen! But you may be wondering: Why is the transplant success rate so low? It’s not so much a shortage of donors (more people are signing up for organ donation all the time). Nor is it a lack of talented surgical teams. Nor even a lack of funding... The biggest problem is that two-thirds of all donated organs are wasted because of the primitive preservation and transportation technology that damages or kills the organs in transit. Allezoe Medical solves this problem and it does so with a revolutionary new technology that’s a GIANT LEAP forward... In fact, the firm’s technology is so advanced that there is practically NO SECOND PLACE (all the better for us while we can still get ALZM shares under $2). Check this amazing advance. Yes, 6 times longer, expanding the current 3 to 4 hour transplant window to 20 to 24 hours. And in many cases, the ALZM system will actually resuscitate and improve the health of the organ in transit (more on this ahead). This ADVANCE will eliminate the tragic 65% wastage, make vastly more healthy organs available for transplant, and significantly reduce costs by removing “procurement” from an emergency-based system. That’s why I’m convinced, early ALZM shareholders will see their shares climb 5 to 10 times higher, and thendouble or triple again during the inevitable bidding war (see the potential big-name buyers just ahead). Hi, I’m Eric Dickson, editor of Breakaway Stocks, the advisory letter for investors seeking fortune-making gains from game- changing companies. In my report today, I’m going to give you all of the decision- making facts... And the first thing to grasp about the organ transplant industry is... The biggest enemy is “time” and ALZM increases the time 6-fold! For example, using the current standard-of- care technology, donor hearts survive just 3 to 4 hours. Of this, 2 hours are needed for the harvesting and transplant operations, leaving just a 1 to 2 hour window for transport to the waiting patient. How far can you take a heart in just an hour or two? Sadly, 73% of all donor hearts die or become too damaged to use because of today’s crude preservation technology that simply puts the heart in a plastic bag on ice in a picnic cooler. I’m not kidding! And I’m sure you’ve seen news footage or a TV drama, showing an emergency medical team running to the helicopter with the Igloo cooler in hand. But here’s the blockbuster change the ALZM technology will now bring... The Life Cradle™ System not only preserves the heart (or other organ) but oxygenates, nourishes, and resuscitates it during transit. A built-in computer also continually monitors its life signs, so the surgeon receives a computerized “health status” report upon its arrival. The extraordinary ramifications of this breakthrough will become crystal clear as we continue, but rest assured you’re getting advance notice on one of the BIGGEST profit opportunities of the decade! ALZM eliminates all of the worst problems and adds several big benefits When ALZM adds 18 to 22 hours to the “transplant viability window,” a host of serious problems are eliminated, including... Surgeon guesswork regarding the organ’s health! Poor donor-to-recipient matches due to short viability time! High risks added by damaged organs and rushed conditions! High labor and transport costs due to emergency system! No time for pre-op testing to help ensure a good outcome! The amazing Life Cradle™ System converts every one of the above problems into a benefit for two reasons — added “time” and a healthy, nourishing transport system. But here’s another benefit you probably didn’t think of... Because extreme urgency is eliminated, the Life Cradle™ can fly on regularly scheduled commercial flights to any location on the continent (here or abroad). The unit is designed to buckle into a normal passenger seat, which eliminates the need for high-priced aircraft and expensive emergency flight and medical crews, which under the current very costly “emergency system” are maintained on standby. From an investment viewpoint... ALZM’s revolutionary advance will make hundreds of thousands more “healthy organs” available for transplant. It will immediately put ALZM on top of a $6 billion procurement market. And it’ll expand the overall transplant market from $21 billion to $60 billion! This is a recipe to dramatically enrich early ALZM shareholders! Just ahead, I’ll show you the company’s amazing technology, and why a 2,000% profit score may be “too conservative,” considering how valuable this company will be to several medical giants... But first, let me give you a handful of key facts that should have you racing to your online trading account to acquire Allezoe Medical shares (symbol ALZM on the OTCBB exchange). Consider that... The Life Cradle™ System has been... Developed through 7 generations of prototypes with constant input and feedback from the top organ transplant centers in America and Europe! Completely tested in 225 preservation experiments–all successful and many producing results beyond anyone’s wildest expectations! Proved in both concept and real-life animal studies, with dozens of peer-reviewed articles published in leading medical journals! Sought out by major medical universities and transplant centers across America and Europe for important studies and the imminent clinical approval trials (on a favored fast-track status)! And most important to investors... ALZM has insurmountable patent protections (4 issued and 4 pending) as well as the enthusiastic backing of the most important figures in the organ transplant industry. The biggest names in “organ transplant” are enthusiastically backing ALZM No less than the illustrious former Wisconsin Governor and Health & Human Services Secretary, Tommy Thompson, is on the OTS corporate board... Secretary Thompson has been a tireless promoter for “more organ donations” and was instrumental in establishing the Organ Donation Breakthrough Collaborative, which has resulted in a dramatic increase in donated organs in recent years. Secretary Thompson enthusiastically joined the OTS board when he realized the biggest problem wasn’t a serious lack of organ donors, but a serious lack of technology to preserve the organs in transit. Again, two-thirds of all organs are wasted, and 73% of all hearts! Also on the ALZM boards... Gene Pearce, who is considered “the patriarch of organ transplant in the US.” Pearce is the founder and Chairman Emeritus of the United Network for Organ Sharing (UNOS), the quasi-governmental body that regulates organ transplantation in the US and controls the highly restricted “wait list.” His association with ALZM should help fast-track FDA approval. These leaders have enthusiastically backedALZMand joined the company’s boards because they know this is a revolutionary technology that will transform the industry and SAVE HUNDREDS OF THOUSANDS OF LIVES! And consider the dollars involved... One heart transplant costs $1 million A typical organ transplant costs between $200,000 and $800,000, and when you add in the immunosuppressant drugs that must be taken for life, the costs go up an additional $150,000 to $300,000 per patient (a big reason pharma companies will want to acquire ALZM). For example... That’s right, 60,000 heart patients could benefit! At $1 million per operation! But no one talks about such a number because, realistically, you can’t get the hearts. ButALZM has a way to dramatically expand the number of donor hearts, as you’ll see just ahead... But first, you should know... ALZM is starting with heart transplants for two reasons – first, it’s a BIG MARKET with a huge unmet need (currently only 27% success rate), and, second, it’s a life- or-death situation where ALZM can make a huge difference! But soon enough, ALZM will branch out to lungs, kidneys, livers, pancreases, intestines, gall bladders, as well as to limbs, because the company’s “proprietary technology” can be adapted to all organs and limbs. In fact... The Life Cradle™ System could be used by our military on the battlefield! The Pentagon is excited about the prospects of reattaching limbs lost by soldiers in battle. The Life Cradle™ System can easily be included in a military unit’s support gear, and the injured soldier and his/her lost limb can be evacuated to the nearest medical facility for surgical repair. Investors can feel proud to help our brave men and women in uniform, but this also saves taxpayer money because it eliminates the need for prosthetics and long-term therapy for our Vets who will now keep their own limbs! It’s a win, win! Are you beginning to see why ALZM shares could quickly climb 10, 20, even 30 times higher? You don’t know the half of it... The ALZM technology will soon rocket a $21 billion industry to $60 billion! THIS IS KEY: Eventually, the ALZM technology should make it possible for everyone who needs a replacement organ to get one... Today, over 100,000 people are on the organ-transplant waitlist, but if everybody who needed an organ could get one, the waitlist would grow to 300,000 patients – and that’s just in the US. The European and Asian markets are twice this size! But what you MUST GRASP is that this $21 billion to $60 billion market expansion makesALZM the most valuable company for acquisition by at least a dozen big medical device and pharmaceutical companies, including... Especially note Johnson & Johnson, which has a medical-device division, plus a pharmaceutical division that includes immunology drugs. Remember, transplant patients must take expensive immunosuppressant drugs for life, and Johnson & Johnson can provide them. Also note Cardinal Health, which has a medical-device division plus a drug distribution division. Analysts say the drug distribution industry in America is mature with very little room to grow. But ALZM would give Cardinal Health tremendous growth potential! And in addition to the giants above, several smaller players, such as Hospira, Biomet or Invacare, could swoop in early and make the acquisition, since it would instantly put them atop a $6 billion (and growing) procurement market! But enough BIG PICTURE stuff! Let me show you the amazing technology at the heart of the Life Cradle™ System and why it will transform the market! Let’s start with the biggest problem ALZM solves – why the vast majority of organs, including 73% of hearts and 92% of lungs, are severely damaged or killed in transit. And at this point, I’m going to switch exclusively to “heart transplants” since this is ALZM’s initial focus – a HUGE market at $1 million per operation, and also the most important in terms of emergency unmet need. ALZM’s super advanced technology replaces primitive system You may be surprise to learn that all donated hearts come from brain-dead but living persons. And it’s always an emotionally charged situation, with the family reluctant to “let go” of their loved one. Unfortunately, the longer the wait, the more the heart deteriorates in the dying body. But a big advantage of the Life Cradle™ System is that it can actually resuscitate the heart in transit (more on this just ahead). But once the family gives its approval, the transplant team leaps into action, harvesting the heart, flushing it with a purifying fluid, and then putting it in a plastic bag on ice in a picnic cooler. And then it’s a “race for time.” And often the transplant surgeon flies by helicopter to the donor, makes the harvest, then flies in the same helicopter back to the transplant center for the operation, all of which is very costly. But in spite of the big rush, a serious problem isn’t addressed... Once the heart is harvested, it continues to metabolize, which means it needs oxygen and life-sustaining nutrients. And if it doesn’t get them it deteriorates and soon dies. Unfortunately, the Igloo cooler provides nothing beyond ice and a “sealed environment.” And the ice damages the heart by freezing surface cells. And, what’s more, without proper nourishment and oxygen, the harvested heart builds up lactate, a biochemical byproduct of stress that causes heart damage. The time factor is so critical that when an organ transplant center receives word a heart is available, the first question is, “How fast can you get it here?” If the answer is over “4 hours,” the heart will be rejected outright. So the biggest limitation is geographic. Just how far can you travel in 1 to 2 hours before the heart is too far gone? And then... When a donated heart arrives at the transplant center, the surgeon makes a physical examination and a “judgment call” on its likelihood of producing a successful outcome. You can’t put a bad heart in somebody because you’ll kill them, so the surgeon’s “judgment call” is critical. And yet he has no scientific data and no time for testing, as the“window of opportunity” to perform a successful transplant is fast closing on him. ALZM completely solves this problem, providing a computer-generated “health status” report, and equally important, added time, if the surgeon wants to do further testing before proceeding. Life-Cradle™ eliminates tragic loss of donor organs To drive this point home, recently 23 donor hearts became available in El Paso (western side of Texas), but since the transplant centers are in Dallas, Houston, and Austin (east side of Texas) not one arrived in time to be safely used. That’s 23 lives that could’ve been saved but weren’t. And 23 donors that wanted to make a difference but didn’t. Sadly, all the hearts were wasted. What’s more, when you have just 1 to 2 hours transit time, you don’t have the luxury of getting the best donor-to-recipient match. Many transplanted hearts are rejected by the recipient’s body because of a poor match, which can result in death, or the need for a second emergency transplant. The worst part is that everything is rushed, and therefore highly risky! A miracle that could soon make early ALZM shareholders rich! Let’s look at the revenue stream... 3-part Life-Cradle™ System provides 3 sources of continuous income The Life-Cradle™ Perfusion System consists of 3 components, each one providing ALZM with a lucrative and steady income stream... External Housing Unit: This piece maintains the ideal temperature, provides a completely sealed unit, contains space for the perfusion system to feed and oxygenate the heart, plus a computer-sensor system that monitors the heart’s health in transit (temperature, tissue health, toxin build-up, oxygen intake and more). The whole unit is small enough to be strapped into a regular passenger seat on commercial flights. And a single unit sells for about $50,000 and will last about 5 years with maintenance.   Internal Heart Container: This is the disposable (one-time-use- only) purified heart container, which fits inside the housing unit and contains a feeding tube to provide the nourishing and oxygenating perfusion fluid. This unit sells for about $15,000, and a new one must be used for each and every heart (or other organ or limb) transplant.   Perfusion Fluid: Think of “perfusion” as a cross between “force” and “infuse,” as the Life Cradle™ Perfusion System literally forces nourishing nutrients and oxygen into the heart (or other organ or limb) to keep it alive and healthy during transit. ALZM’s proprietary perfusion fluid sells for $300 per liter. And depending on the type of transplant and distance traveled, between 4 and 9 liters will be used, with an average cost of $2,000 per operation. KEY POINT: during the development of the Life Cradle™ Perfusion System, the ALZM team consulted with Dr. Joe Tector of the Midwest Heart Surgery Institute, and he related the following story... Early in his career with one of his first heart transplants he “hand perfused” the donor heart with Ringer’s Solution, a nourishing fluid that was proven beneficial to heart health in 1885 by British physician Dr. Sydney Ringer. Incredibly, Dr. Tector’s patient lived 25 years following the transplant, double the average. Recipients of ALZM “perfused hearts” likely to live much longer! ALZM’s proprietary perfusion fluid is far more advanced than the 125 year-old Ringer’s Solution, but the important takeaway here is that advance perfusion technology can indeed resuscitate damaged hearts, and recipients receiving “ALZM perfused hearts” will likely live much longer than the current average of just 11 years! That’s a miracle in itself, but it also opens up a far bigger immunosuppressant drug market, making ALZM a highly desirable acquisition by one of the big pharma companies. In any case, the Life Cradle™ System solves so many problems and offers so many benefits that it will instantly become the first choice of virtually every transplant operation in the US and abroad. Here are the immediate benefits ALZM brings to the organ-transplant industry... Greatly expands the geographical reach of donate dorgans! Vastly improves donor-to-recipient organ matches! Dramatically increases organ usage, ending tragic wastage! High labor and transport costs due to emergency system! No time for pre-op testing to help ensure a good outcome! Significantly decreases mortality rates and SAVES LIVES! Eliminates very costly emergency-based system! Provides surge on with scientific health-status report, thus eliminating guesswork and improving results. Dramatically expands the organ-transplant market, boosting revenues from $21 billion to $60 billion annually! Okay, we’re almost done, but there’s one more “startling fact” you must know before we get to revenues, profits, and the potential buyout value of this remarkable company.. Remember, I promised to tell you how the ALZM technology can dramatically expand organ donations, so that ultimately every patient who needs a replacement organ can get one? Well, look here... Right now, severely damaged hearts, such as those from badly burned victims who won’t survive, as well as hearts from deceased persons, are automatically rejected. But with theALZM technology the... Donor heart pool can be greatly expanded with damaged and deceased hearts! Many transplant surgeons believe many damaged and deceased organs can be resuscitated. No, this isn’t science fiction, and some of America’s most prestigious medical centers are right now working with ALZM on this... First example: Dr. Michael Jesson, who heads the heart transplant team at the University of Texas Southwestern Medical School, recently harvested a badly damaged heart from a burn victim who had inhaled toxic fumes. The heart was in very bad shape, but he put it into the Life Cradle™ Perfusion System and flew back to the transplant center... When Dr. Jesson removed the heart from the Life CradleTM 12 hours later and examined it, he concluded it was in much better shape than when it first went in. In fact, it was in such good shape, he said he would NOT have hesitated to use it in a real transplant. Second example: the heart-transplant team at theDuke University Medical Center contacted ALZM to use the Life Cradle™ Perfusion System to resuscitate hearts from deceased persons. According to the Duke University medical team, and many other experts in this field, hearts from deceased donors can be resuscitated if harvested within 30 to 60 minutes of death and given the ALZM perfusion therapy. The Duke University Medical Team will use the Life Cradle™ System to revive deceased hearts, and pre-clinical studies are set to begin soon! What’s missing are the hearts. But very soon ALZM could make them available! And at $1 million per operation — well, make that $970,000 because ALZM reduces the cost of procurement – the heart transplant market could potentially jump to $58 billion in America alone!